Amgen vs. Eli Lilly: GLP-1 obesity-drug hype is reshaping how investors price two biotech giants

Eli Lilly and Amgen have become two of the best-known names in the race to treat obesity with GLP-1-based medicines, but they are currently being valued in sharply different ways. In a market-focused comparison published by Yahoo Finance, the central question is whether the growing “GLP-1 mania” has pushed Eli Lilly’s stock price high enough that investors should instead focus on Amgen, which the analysis says trades at a markedly lower valuation multiple.

The piece highlights that Amgen is positioned as the cheaper option on valuation, described as trading at roughly half the valuation multiple of Eli Lilly. At the same time, the comparison claims Amgen’s free cash flow strength is currently outpacing the narrative around Lilly, suggesting that investors may be paying more for Lilly’s growth expectations than for near-term cash generation.

That framing matters because the obesity-drug category has been a primary driver of investor sentiment across large-cap biotech. The market sees GLP-1 therapies as capable of expanding well beyond diabetes care, with obesity drug demand expected to rise as more patients become eligible and as insurers and health systems adjust coverage. Against that backdrop, Lilly’s name carries a premium in many investor conversations, the Yahoo Finance comparison implies, because its obesity pipeline and commercial positioning are closely watched by the market.

Still, the article’s argument is not simply that Lilly is overvalued. It suggests that the explosive growth narrative around obesity drugs adds complexity, because it can justify paying up for companies tied to the segment’s upside. In other words, even if Amgen looks cheaper on valuation and generates more free cash flow, Lilly’s stock may reflect not just current results but the expectation that GLP-1 demand growth will remain strong for years.

The comparison also positions Amgen as a company that investors may be able to underwrite with a more traditional financial lens, emphasizing cash flow rather than relying primarily on the momentum of obesity drug expectations. For equity investors, free cash flow is often treated as a measure of how much cash a business can generate after operating costs and capital spending, which can influence how resilient earnings may be if growth slows or if pricing becomes more competitive.

For Lilly, the debate is essentially about what portion of obesity-drug optimism has already been capitalized into the stock. The Yahoo Finance analysis frames this as the key investor decision for 2026, tying valuation and cash generation to the question of whether the GLP-1 growth curve the market is currently tracking is likely to persist at the same pace or whether it will normalize.

The broader sector context is that GLP-1 obesity drugs have shifted biotech valuation frameworks. Instead of focusing solely on pipeline milestones and speculative future launches, markets increasingly anchor on commercialization scale, capacity to expand indications, and the durability of demand. That shift can produce wide valuation gaps between companies that are both in the same therapeutic space but differ in how investors perceive their near-term execution and long-term market share.

What the Yahoo Finance comparison does not provide in detail, and therefore what remains unclear, is the specific valuation math behind the “half the multiple” statement, the underlying free cash flow trends cited, and any company-by-company segment breakdowns. The post also does not disclose, within the portion available here, how each firm’s obesity-related portfolio compares on clinical outcomes, pricing, or competitive dynamics. Those details typically require deeper review of company filings, guidance, and segment reporting to validate the investment framing behind the headline comparison.